Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era

Liang, Emily C.; Craig, Juliana; Torelli, Stefan; Cunanan, Kristen; Iglesias, María; Arai, Sally; Frank, Matthew J.; Johnston, Laura; Lowsky, Robert; Meyer, Everett; Miklos, David B.; Negrin, Robert S.; Rezvani, Andrew R.; Shiraz, Parveen; Shizuru, Judith A.; Sidana, Surbhi; Weng, Wen‐Kai; Bharadwaj, Sushma; Muffly, Lori

doi:10.1016/j.jtct.2022.05.010

Cited by 5 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the best strategies in the treatment of high-risk ALL patients is the allogeneic transplantation of HSCs. Nevertheless, complications such as graft versus host disease (GVHD), can compromise its efficacy [78,79]. Although the role of neutrophils in CLL has traditionally been underestimated, recent studies have brought attention to a notable trend: CLL patients exhibit a higher inclination for NETs release compared to their healthy counterparts.…”

Section: Regulation Of Netosis In Leukemiamentioning

confidence: 99%

Deregulation of New Cell Death Mechanisms in Leukemia

Favale,

Donnarumma,

Capone

et al. 2024

Cancers

View full text Add to dashboard Cite

Hematological malignancies are among the top five most frequent forms of cancer in developed countries worldwide. Although the new therapeutic approaches have improved the quality and the life expectancy of patients, the high rate of recurrence and drug resistance are the main issues for counteracting blood disorders. Chemotherapy-resistant leukemic clones activate molecular processes for biological survival, preventing the activation of regulated cell death pathways, leading to cancer progression. In the past decade, leukemia research has predominantly centered around modulating the well-established processes of apoptosis (type I cell death) and autophagy (type II cell death). However, the development of therapy resistance and the adaptive nature of leukemic clones have rendered targeting these cell death pathways ineffective. The identification of novel cell death mechanisms, as categorized by the Nomenclature Committee on Cell Death (NCCD), has provided researchers with new tools to overcome survival mechanisms and activate alternative molecular pathways. This review aims to synthesize information on these recently discovered RCD mechanisms in the major types of leukemia, providing researchers with a comprehensive overview of cell death and its modulation.

show abstract

Section: Regulation Of Netosis In Leukemiamentioning

confidence: 99%

Deregulation of New Cell Death Mechanisms in Leukemia

Favale,

Donnarumma,

Capone

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…In this scenario allo-HSCT still represents an effective therapeutic treatment and is currently part of adult ALL standard clinical care (36, 37). However, a significant percentage (~40%) of patients will relapse after allo-HSCT, while other (15 to 26%) will die due to non-relapse mortality (NRM) (37)(38)(39) despite recent advances in transplant management (38,39). In keeping with these premises, in young adult and adult patients allo-HSCT is currently part of postconsolidative therapy in case of high-risk features such as Phpositivity, Ph-like disease, and persistent MRD as assessed by either MFC or RQ-PCR (11,12).…”

Section: Mfc Mrd Monitoring In Adult All Patients Undergoing Allo-hsc...mentioning

confidence: 99%

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Tecchio

Russignan²,

Krampera³

2023

Front. Oncol.

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a survival benefit to adult patients affected by acute lymphoblastic leukemia (ALL). However, to avoid an overt disease relapse, patients with pre or post transplant persistence or occurrence of measurable residual disease (MRD) may require cellular or pharmacological interventions with eventual side effects. While the significance of multiparametric flow cytometry (MFC) in the guidance of ALL treatment in both adult and pediatric patients is undebated, fewer data are available regarding the impact of MRD monitoring, as assessed by MFC analysis, in the allo-HSCT settings. Aim of this article is to summarize and discuss currently available information on the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT. The significance of MFC-based MRD according to sensitivity level, timing, and in relation to molecular techniques of MRD and chimerism assessment will be also discussed.

show abstract

Unravelling ALL: The Keys to Improved Post-Transplant Survival in Acute Lymphoblastic Leukemia

Pasvolsky

Popat

2022

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era

Cited by 5 publications

References 28 publications

Deregulation of New Cell Death Mechanisms in Leukemia

Deregulation of New Cell Death Mechanisms in Leukemia

Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Unravelling ALL: The Keys to Improved Post-Transplant Survival in Acute Lymphoblastic Leukemia

Contact Info

Product

Resources

About